ReviewCarcinogenesis2022
Dissecting intratumor heterogeneity in HCC: new research strategies and clinical implications.
Review in Carcinogenesis, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed.
- Lipid droplet-associated gene signatures classify metabolic subtypes and identify PLIN3 as a key driver in hepatocellular carcinoma.Genes & diseases · 2026Article
- Development of a G2/M checkpoint subtype classifier for guiding precision therapy in liver hepatocellular carcinoma patients.Cancer cell international · 2026Article
- Integrative Sequencing and Proteogenomic Approaches to Intratumoral Heterogeneity in Cholangiocarcinoma: Implications for Precision Diagnosis and Therapy.Medical sciences (Basel, Switzerland) · 2026Review
- Chondroitin sulfate proteoglycan 4 (CSPG4) overexpression as an oncogenic driver and prognostic marker for unfavorable outcomes in hepatocellular carcinoma.World journal of surgical oncology · 2025Article
- Machine learning developed LKB1-AMPK signaling related signature for prognosis and drug sensitivity in hepatocellular carcinoma.Scientific reports · 2025Article
- The long noncoding RNA RMRP-miR-3135a-SV2A axis promotes the development of hepatocellular carcinoma.Journal of gastrointestinal oncology · 2025Article
- An immune cell activation signature reflected hepatocellular carcinoma heterogeneity and predicted clinical outcomes.Frontiers in immunology · 2025Article
- Molecular profiling of circulating tumor cells guides effective EGFR inhibitor treatment in advanced hepatocellular carcinoma: a case report.Frontiers in oncology · 2025Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Hepatocellular carcinoma (HCC) accounts for the majority of liver cancers and is driven by a multitude of viral, metabolic, and lifestyle factors initiating liver injury that subsequently progresses to cancer. Despite significant medical advancements, current treatment options are limited in their efficacy and overall survival remains poor. Recent studies have suggested that intratumor heterogeneity may play a significant role in treatment response, resistance, and overall prognosis. In this review, we will outline new techniques that utilize both human samples and non-human models to evaluate intratumor heterogeneity. Additionally, we will provide an overview of the clinical implications of intratumor heterogeneity on patients with HCC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.